Heart Disease News and Research

Latest Heart Disease News and Research

BioClinica third quarter service revenues increase to $15.8 million

BioClinica®, Inc., a global provider of clinical trial management services, today announced its financial results for the three and nine months ended September 30, 2010.

From Clario 3 Nov 2010

Cambridge Heart third quarter sales increase 21% to $793,000

Cambridge Heart, Inc., today reported results for the three and nine months ended September 30, 2010.

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

IDEV receives FDA marketing clearance for SUPERA VERITAS Transhepatic Biliary System

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance to market the SUPERA VERITAS Transhepatic Biliary System.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

MiCardia receives European CE Mark approval for enCor Mitral Valve Repair System

MiCardia Corporation announced today that it has received the CE Mark to begin marketing the Company's enCor™ Mitral Valve Repair System in the European Union.

3 Nov 2010

Lifestyle changes and natural supplements can control blood sugar levels

The holiday season can make it challenging for people with diabetes to keep their blood sugar levels stable. Diabetes expert, Dr. Isaac Eliaz recommends prevention through a number of lifestyle changes and natural supplements.

3 Nov 2010

Effort exerted on cognitive task influenced by masked action or inaction cues

People may have a better memory for birthdays that are closer to their own: Volunteers recalling their friends' birthdays tended to remember birthdays that were closer to their own than birthdays that were farther away from their own birthday.

3 Nov 2010

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

Value-Based Insurance Design - a concept created at the University of Michigan and incorporated in the nation's new health care reform law - is the focus of an upcoming national policy journal.

3 Nov 2010

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

The North American Center for Continuing Medical Education, LLC , in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced several key sessions on the treatment of atrial fibrillation at the upcoming Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, to be held December 9-11, 2010, at the Washington Hilton in Washington, DC.

3 Nov 2010

Cardiovascular Systems enters settlement agreement with ev3

Cardiovascular Systems, Inc. announced today that it has entered into a settlement agreement with ev3, Inc., now part of Covidien plc. The agreement dismisses all claims and counterclaims in the employment lawsuit between the two companies. The litigation stems from a suit ev3 originally filed against CSI in 2007 related to employees who joined CSI from ev3.

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

Study suggests heredity may play a role in determining infant's susceptibility to AOP

A potentially life-threatening challenge characterized by pauses in breathing that can last for more than 20 seconds, apnea of prematurity (AOP) affects more than 50 percent of premature infants and is almost universal in the smallest of preemies. Caused in part by an underdeveloped central nervous system that can't adequately regulate breathing outside of the womb, especially during sleep, AOP is not yet fully understood by scientists and remains a grave concern among neonatologists and parents alike.

3 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

UIC awarded $12M to study acquired and familial causes of heart failure

Researchers at the University of Illinois at Chicago have been awarded more than $12 million by the National Heart, Lung, and Blood Institute to investigate both the acquired and familial causes of heart failure -- with the aim of identifying markers for diagnosis and targets for cures.

3 Nov 2010

NIH awards Nemours/Alfred I. duPont Hospital for Children additional $9.5M research grant

The Center for Pediatric Research (CPR) at the Nemours/Alfred I. duPont Hospital for Children was recently awarded an additional 5-year, $9.5-million Center for Biomedical Research Excellence (COBRE) grant from the National Institutes of Health (NIH), National Center for Research Resources (NCRR). This competitive award will allow Nemours to continue to expand the CPR and support the recruitment of additional faculty to this diverse pediatric clinical and research facility.

3 Nov 2010

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

3 Nov 2010

South Dakota passes strong smoke-free law

The people of South Dakota delivered a historic victory for health and the right to breathe clean air by overwhelmingly approving Referred Question 12 that makes almost all workplaces, including restaurants, bars and gaming facilities, smoke-free. With bipartisan support, South Dakota is the 29th state to pass a strong smoke-free law that includes all restaurants and bars.

3 Nov 2010

JenaValve commences CE-Mark study for transapical TAVI system

JenaValve™ Technology, Inc., a medical device company specialized in developing transcatheter valve replacement products, announced today the start of its multicenter CE-mark study. The first two implantations of its transapical TAVI system were performed by Dr. med. Hendrik Treede at the Universitäres Herzzentrum Hamburg.

3 Nov 2010

Heart Disease News and Research

Latest Heart Disease News and Research

BioClinica third quarter service revenues increase to $15.8 million

Cambridge Heart third quarter sales increase 21% to $793,000

Top 10 Medical Innovations for 2011

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

IDEV receives FDA marketing clearance for SUPERA VERITAS Transhepatic Biliary System

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

MiCardia receives European CE Mark approval for enCor Mitral Valve Repair System

Lifestyle changes and natural supplements can control blood sugar levels

Effort exerted on cognitive task influenced by masked action or inaction cues

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

Cardiovascular Systems enters settlement agreement with ev3

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

Study suggests heredity may play a role in determining infant's susceptibility to AOP

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

UIC awarded $12M to study acquired and familial causes of heart failure

NIH awards Nemours/Alfred I. duPont Hospital for Children additional $9.5M research grant

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

South Dakota passes strong smoke-free law

JenaValve commences CE-Mark study for transapical TAVI system

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Heart Disease News and Research

Latest Heart Disease News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in